News | January 19, 2015

Direct Flow Medical Receives $32 Million in New Financing

Chris Richardson appointed as chief commercial officer

CT systems, CT angiography, FFR Catheters, Direct Flow Medical Transcatheter

Image courtesy of Direct Flow Medical

January 19, 2015 — Direct Flow Medical Inc. announced the closing of a new round of financing for the company totaling $32 million. The company also announced the appointment of Chris Richardson as its first chief commercial officer to support global growth of the Direct Flow Medical Transcatheter Aortic Valve System. With the addition of Richardson, Dan Rose has been appointed vice president and general manager of Europe, the Middle East and Africa (EMEA).  

The $32 million financing includes $17 million in private equity led by investor SV Life Sciences and the second tranche of a $50 million debt facility from PDL BioPharma worth $15 million. Proceeds will be used to complete the U.S. SALUS pivotal trial and fuel growth of the Direct Flow Medical system outside of the United States.

The benefits of the Direct Flow Medical Transcatheter Aortic Valve System are enabled by its design, which features a metal?free frame. Rather than a metal stent, the Direct Flow Medical System incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. The saline/contrast solution is easily exchanged for a quick?curing polymer that solidifies and secures the valve in place once optimal positioning is reached.

The double?ring design of the valve creates a tight seal around the annulus. The system is fully repositionable and retrievable up until polymer exchange. The system avoids rapid pacing of the heart during deployment, and does not require post?dilatation following placement. The Direct Flow Medical Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis who are at extreme risk for surgical aortic valve replacement (SAVR).The metal?free design enables a low?profile, fully sheathed delivery system for all valve sizes that minimizes vascular complications and improves hemodynamic outcomes.

The Direct Flow Medical Transcatheter Aortic Valve System is commercially available in Europe. In the United States, the company is working towards regulatory approval and is currently enrolling patients in its SALUS pivotal trial.

For more information: www.directflowmedical.com

 

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init